#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14424	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2330	616.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1630	1630	C	892	C	816	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14424	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2330	616.8	0	HET	.	.	.	C1200T	.	1200	1200	C	1646	1646	C	836	C,T	587,182	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26244	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	744.6	0	.	n	.	0	T695C	SNP	695	695	T	995	995	C	831	C,T,A	768,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26244	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	744.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1637	1637	A	856	A,G	804,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26244	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	744.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2271	2271	C	843	C	776	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26244	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	744.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2897	2897	T	805	T	768	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26244	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3511	744.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2345	2345	A	812	A	773	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1976	folP	852	852	100.0	folP.l15.c17.ctg.1	1596	122.9	1	SNP	p	R228S	1	.	.	682	684	AGC	968	970	AGC	195;195;197	A;G;C	186;184;186	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5362	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3431	155.8	1	SNP	p	S91F	0	.	.	271	273	TCC	639	641	TCC	176;176;181	T;C,T;C	170;171,1;174	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5362	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3431	155.8	1	SNP	p	D95N	0	.	.	283	285	GAC	651	653	GAC	182;185;185	G;A,G;C	177;176,1;179	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5362	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3431	155.8	1	SNP	p	D95G	0	.	.	283	285	GAC	651	653	GAC	182;185;185	G;A,G;C	177;176,1;179	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1594	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1163	135.5	0	.	p	.	0	A39T	NONSYN	115	117	GCC	388	390	ACC	200;201;202	A;C;C	174;186;187	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1594	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1163	135.5	0	.	p	.	0	R44H	NONSYN	130	132	CGC	403	405	CAC	193;193;191	C;A;C	178;174;179	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1594	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1163	135.5	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	586	588	CAC	205;205;201	C,T;A;C	192,1;192;188	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1594	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1163	135.5	1	SNP	p	G45D	0	.	.	133	135	GGC	406	408	GGC	197;198;197	G;G;C	184;184;185	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	916	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c30.ctg.1	979	93.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	162.1	1	SNP	p	D86N	0	.	.	256	258	GAC	721	723	GAC	178;179;180	G;A;C	170;170;173	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	162.1	1	SNP	p	S87R	0	.	.	259	261	AGT	724	726	AGT	185;185;186	A;G;T	178;176;176	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	162.1	1	SNP	p	S87I	0	.	.	259	261	AGT	724	726	AGT	185;185;186	A;G;T	178;176;176	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	162.1	1	SNP	p	S87W	0	.	.	259	261	AGT	724	726	AGT	185;185;186	A;G;T	178;176;176	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5070	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3117	162.1	1	SNP	p	S88P	0	.	.	262	264	TCC	727	729	TCC	185;183;179	T;C;C	177;172;172	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4220	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2804	149.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1551	1553	GGC	206;204;206	G;G;C,T	193;191;191,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1223	1225	GCA	219;224;226	G;C;A	208;208;214	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1226	1228	ATC	227;227;230	A;T;C	214;211;215	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1238	1240	GTG	228;226;225	G;T;G	212;209;210	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1238	1240	GTG	228;226;225	G;T;G	212;209;210	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1742	1744	ACC	177;177;179	A;C;C	160;163;166	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1796	1798	GCG	183;184;185	G;C;G	161;149;158	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1796	1798	GCG	183;184;185	G;C;G	161;149;158	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1919	1921	GGC	121;121;120	G;G;C	115;115;114	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1928	1930	GGC	116;116;115	G;G;C	108;109;107	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3854	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2367	162.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1946	1948	CCG	113;113;110	C;C;G	85;85;83	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5640	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	2992	187.6	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1607	1609	CTG	226;227;226	C;T;G	200;196;199	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2296	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1771	129.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	526	526	C	162	C	149	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	426	428	GGA	218;221;223	G;G;A	211;209;211	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	0	.	p	.	0	T87A	NONSYN	259	261	ACT	543	545	GCT	173;172;175	G;C;T	143;146;137	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	0	.	p	.	0	F135L	NONSYN	403	405	TTT	687	689	CTT	195;193;194	C;T;T	184;183;183	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	711	713	GGA	183;180;178	G;G;A	173;169;168	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	0	.	p	.	0	D171G	NONSYN	511	513	GAT	795	797	GGT	201;204;207	G;G;T	185;187;186	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	0	.	p	.	0	G189S	NONSYN	565	567	GGC	849	851	AGC	212;210;208	A;G,A;C	196;192,1;192	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	915	915	T	204	T	193	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	1	SNP	p	G120K	0	.	.	358	360	GGT	642	644	GGT	204;203;207	G,A;G,A;T,G	189,1;187,1;188,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	1	SNP	p	A121N	0	.	.	361	363	GCC	645	647	GCC	204;203;204	G,A;C,A;C	187,1;187,1;190	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2590	porB1b	1035	1035	95.73	porB1b.l15.c17.ctg.1	1476	173.7	1	SNP	p	A121D	0	.	.	361	363	GCC	645	647	GCC	204;203;204	G,A;C,A;C	187,1;187,1;190	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9766	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4842	201.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2051	2053	AAT	229;224;222	A;A;T	219;214;211	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1022	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1170	87.0	1	SNP	p	V57M	1	.	.	169	171	ATG	627	629	ATG	209;208;208	A,C;T;G	196,1;196;195	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
